MacroChem Acquires Virium Pharm...(Martin and Paul Echenberg have resignedf...)

Date:4/23/2008

Martin and Paul Echenberg have resigned from the Company's board of directors. Messrs. Robert DeLuccia, Mark Alvino and Jeffrey Davis remain on the board. Dr. James Pachence and David Luci, Esq. have been added to the board. Mr. Luci had served as MacroChem's Chief Financial Officer, General Counsel & Vice President, Corporate Development. In his capacity as President & Chief Business Officer, Mr. Luci will assume the responsibilities of Chief Operating Officer, and continue his responsibilities as Chief Financial Officer and General Counsel. Mr. DeLuccia also commented, "Special thanks are in order to the departing Directors for their years of service to the Company and their supportive role in this transaction for the best interests of our stockholders."

About Virium

Virium is a non-public, development stage company whose business is developing and commercializing novel therapeutics with a focus in oncology. Virium has in-licensed opportunities for the development and commercialization of several oncology-related compounds and technologies in order to advance them along the regulatory and clinical pathways toward commercial approval. These opportunities involve compounds that Virium believes show promising late-stage, pre-clinical or early clinical data.

Virium's VP701 development program involves a novel nucleoside analogue, 4'-thio-beta-D-arabinofuranosylcytosine. This compound is within a certain class of anti-cancer drugs generally characterized as cytotoxic agents with proven success in certain blood-borne cancers. In pre-clinical studies, VP701 has shown activity against leukemia, colon, lung, prostate, pancreatic, renal, and breast cancers. There have been two dose-escalation Phase I clinical trials completed in patients with advanced solid tumor malignancies, showing encouraging results.

Virium's VP101 development program involves an amino acid derivative commonly known as sodium phenylbutyrate ("PB"). Through sponsorships with
'/>"/>

SOURCE MacroChem Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. MacroChem Appoints David P. Luci as New CFO
2. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
3. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
4. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
5. United BioSource Acquires Leading Publication Planning Software and Services Company
6. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
7. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
8. Aida Acquires High-Level Research Institute in China
9. Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company
10. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
11. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases